1h Free Analyst Time
The acute myeloid leukemia (AML) treatment market in apac is forecasted to grow by USD 305.8 million during 2023-2028, accelerating at a CAGR of 13.9% during the forecast period. The report on the acute myeloid leukemia (AML) treatment market in apac provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high incidence of acute myeloid leukemia, advancement in pharmacology and molecular biology in apac, and rising adoption of generic drugs.
The acute myeloid leukemia (AML) treatment market in apac is segmented as below:
By Type
- Chemotherapy
- Stem cell transplantation
- Others
By Geographical Landscape
- APAC
The report on the acute myeloid leukemia (AML) treatment market in apac covers the following areas:
- Acute Myeloid Leukemia (AML) Treatment Market in APAC sizing
- Acute Myeloid Leukemia (AML) Treatment Market in APAC forecast
- Acute Myeloid Leukemia (AML) Treatment Market in APAC industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the acute myeloid leukemia (AML) treatment market in apac: AbbVie Inc., Agios Inc., Amgen Inc., Astellas Pharma Inc., Astex Pharmaceuticals Inc., Bristol Myers Squibb Co., CTI BioPharma Corp., Cyclacel Pharmaceuticals, Inc., Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Jazz Pharmaceuticals Plc, Johnson and Johnson Services Inc., MEI Pharma Inc, Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is car t-cell therapy for aml."
According to the report, one of the major drivers for this market is the high incidence of acute myeloid leukemia.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Agios Inc.
- Amgen Inc.
- Astellas Pharma Inc.
- Astex Pharmaceuticals Inc.
- Bristol Myers Squibb Co.
- CTI BioPharma Corp.
- Cyclacel Pharmaceuticals Inc.
- Daiichi Sankyo Co. Ltd.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Jazz Pharmaceuticals Plc
- Johnson and Johnson Services Inc.
- MEI Pharma Inc
- Novartis AG
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
